Mastermind Session: A Comparison of Currently Available Spatial Technologies Including Spatial Transcriptomics & Proteomics
Time: 3:45 pm
day: Conference Day 1- Part 2
Details:
This session is your opportunity to share your most pressing challenges and work as a group to come up with solutions that you can implement right away! Each table group will have 25 minutes to discuss their thoughts on the given topic. Groups will then share their findings with all attendees during the final 15 minutes, giving you maximum exposure to new ideas!
Some points of discussion can include:
- Evaluating the various spatial technologies industry utilizes for drug development including low-plex to highplex platforms
- Understanding the pros and cons of spatial transcriptomics or proteomics including cost, timelines and ease of use
Moderated by Deidre Dalmas, Director – Global Investigative Safety, Nonclinical Safety Project Lead, Formerly GSK